TriSalus Life Sciences (TLSI) Projected to Post Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 15th. Analysts expect TriSalus Life Sciences to post earnings of ($0.20) per share and revenue of $9.04 million for the quarter. TriSalus Life Sciences has set its FY 2025 guidance at EPS.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Thursday, March 27th. The company reported ($0.35) EPS for the quarter, meeting analysts’ consensus estimates of ($0.35). The firm had revenue of $8.26 million for the quarter, compared to analysts’ expectations of $8.12 million. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Price Performance

NASDAQ TLSI opened at $5.07 on Wednesday. TriSalus Life Sciences has a 1 year low of $3.50 and a 1 year high of $10.24. The company has a market cap of $163.62 million, a price-to-earnings ratio of -2.04 and a beta of 0.50. The stock’s fifty day moving average price is $5.40 and its 200 day moving average price is $4.98.

Wall Street Analysts Forecast Growth

TLSI has been the subject of a number of analyst reports. Roth Mkm reaffirmed a “buy” rating and issued a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday, January 24th. Canaccord Genuity Group restated a “buy” rating and issued a $11.00 price target on shares of TriSalus Life Sciences in a research report on Friday, March 28th. Finally, Lake Street Capital initiated coverage on shares of TriSalus Life Sciences in a research note on Thursday, February 13th. They set a “buy” rating and a $10.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $10.93.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.